| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/24/2002 | WO2001014405A3 Methods of obtaining 2-methoxyestradiol of high purity |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000066142A3 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 01/24/2002 | WO2000053168A3 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010351 Anticancer agents |
| 01/24/2002 | US20020010344 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 01/24/2002 | US20020010316 Thiazole derivatives |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010216 Mixture of norepinephrine reuptake inhibitors and antimuscarinic agents; treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence. |
| 01/24/2002 | US20020010200 Optically pure (-) amlodipine compositions |
| 01/24/2002 | US20020010195 Mitochondria protecting agents for treating mitochondria associated diseases |
| 01/24/2002 | US20020010192 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010189 For treatment of sexual disorders, male erectile dysfunction |
| 01/24/2002 | US20020010183 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 01/24/2002 | US20020010174 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010158 Derivatives of 5-pyridylalkylphosphonates and 5-pyridylalkylmalonates useful drugs for treatment of cardiovascular related diseases and diabetes mellitus related diseases |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 01/24/2002 | US20020009743 That proliferate in an in vitro culture, obtained by differentiating primate pluripotent stem (pPS) cells, where certain proportion of cells are committed to form neuronal cells, glial cells, or both; screening compounds |
| 01/24/2002 | US20020009483 Topical administration of oxazolidinones for transdermal delivery |
| 01/24/2002 | DE19963234A1 New N,N-disubstituted piperazine and diazacycloheptane derivatives useful in treatment of hyperlipidemia, atherosclerosis, diabetes mellitus, adiposity and pancreatitis |
| 01/24/2002 | DE10034233A1 Tocotrienolchinon-Cyclisierungsprodukte Tocotrienolquinone cyclization products |
| 01/24/2002 | CA2429008A1 Lipid-rich plaque regressing agents |
| 01/24/2002 | CA2416813A1 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis |
| 01/24/2002 | CA2416452A1 Novel proteins and nucleic acids encoding same |
| 01/24/2002 | CA2416384A1 Sulfone derivatives, their production and use |
| 01/24/2002 | CA2416248A1 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | CA2416245A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | CA2416036A1 Substituted amidoalkyl-uracils as parp inhibitors |
| 01/24/2002 | CA2415961A1 Production method of 1-substituted-1,2,3-triazole derivatives |
| 01/24/2002 | CA2415935A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | CA2415896A1 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | CA2415665A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | CA2415557A1 Compounds for the treatment of sexual dysfunction |
| 01/24/2002 | CA2415392A1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | CA2415128A1 An implantable or insertable therapeutic agent delivery device |
| 01/24/2002 | CA2384041A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/23/2002 | EP1174431A2 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors |
| 01/23/2002 | EP1174134A1 Compositions for treating brain infarction |
| 01/23/2002 | EP1173595A1 Use of coxsackie viruses for improving cell transfection |
| 01/23/2002 | EP1173568A2 Laminin 2 and methods for its use |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173564A1 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
| 01/23/2002 | EP1173561A2 Non-invasive method for detecting target rna |
| 01/23/2002 | EP1173485A1 Human antibodies to staphylococcus aureus |
| 01/23/2002 | EP1173484A1 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| 01/23/2002 | EP1173478A1 49 human secreted proteins |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173469A2 Adhesion modulatory peptides and methods for use |
| 01/23/2002 | EP1173468A1 Integrin receptor antagonists |
| 01/23/2002 | EP1173465A1 Novel human voltage-gated potassium channel |
| 01/23/2002 | EP1173464A2 Process of purifying phytosterols from wood or plant-derived sources by means of metal salt complexes and compositions resulting therefrom |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173455A2 Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments |
| 01/23/2002 | EP1173440A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands |
| 01/23/2002 | EP1173434A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/23/2002 | EP1173424A1 Pyrimidine compounds |
| 01/23/2002 | EP1173418A1 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide |
| 01/23/2002 | EP1173403A1 Salts of asiatic and madecassic acid suitable for the preparation of pharmaceutical and cosmetic compositions |
| 01/23/2002 | EP1173254A2 Novel treatment of neurotraumatic conditions with a raf inhibitor |
| 01/23/2002 | EP1173215A1 Over-coated chewing gum formulations |
| 01/23/2002 | EP1173214A2 Medicinal substance utilization for preventing nitrate tolerance |
| 01/23/2002 | EP1173201A1 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 01/23/2002 | EP1173197A2 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 01/23/2002 | EP1173195A2 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
| 01/23/2002 | EP1173190A1 Treatment of acute myocardial infarction with a substance related to the growth hormone axis |
| 01/23/2002 | EP1173183A2 Use of compounds with a nitrogen-oxygen heterocycle |
| 01/23/2002 | EP1173175A1 A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping |
| 01/23/2002 | EP1173172A1 Synergistic effects of amlodipine and atorvastatin |
| 01/23/2002 | EP1173170A1 Pyrrolidine modulators of chemokine receptor activity |
| 01/23/2002 | EP1173169A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 01/23/2002 | EP1173165A1 Cardiovascular and bone treatment using isoflavones |
| 01/23/2002 | EP1173164A2 Estrogen receptor-beta ligands |
| 01/23/2002 | EP1173160A1 (e)-styryl sulfone anticancer agents |
| 01/23/2002 | EP1173155A1 Gum pad for delivery of medication to mucosal tissues |
| 01/23/2002 | EP1173149A1 Cosmetic and/or dietetic composition comprising a mixture of lycopene and olive leaf extract |
| 01/23/2002 | EP1025100B1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
| 01/23/2002 | EP0854711B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 01/23/2002 | EP0704056B9 Leukocyte adhesion assay |
| 01/23/2002 | EP0623144B1 Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock |
| 01/23/2002 | CN1332849A Methods and compositions to lower plasma cholesterol levels |
| 01/23/2002 | CN1332801A Connective tissue growth factor (CTGF) and methods of use |
| 01/23/2002 | CN1332741A Pyrazolopyridine derivatives as selective COX-2 inhibitors |
| 01/23/2002 | CN1332740A 5HT antagonists for antidepressant therapy |
| 01/23/2002 | CN1332737A Thrombin inhibitors |
| 01/23/2002 | CN1332734A Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity |
| 01/23/2002 | CN1332731A Substituted benzimidazoles and their prep. and use |
| 01/23/2002 | CN1332727A 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| 01/23/2002 | CN1332726A Pyrrolidine compounds and medicinal utilizaion thereof |
| 01/23/2002 | CN1332724A N-arylsulfonyl amino acid omega amides |
| 01/23/2002 | CN1332723A Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| 01/23/2002 | CN1332636A Composition for prevention and/or |
| 01/23/2002 | CN1332628A Method of treating sexual disturbances |
| 01/23/2002 | CN1332626A Inhalation system |
| 01/23/2002 | CN1332240A Superoxide dismutase-4 |
| 01/23/2002 | CN1332175A Jackfruit cycloalkane triterpenic saponin as one new compound and its application in the treatment of cardiovascular disease |
| 01/23/2002 | CN1332167A Eprosartan dihydrate and its prep. |